Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas
Authors:
- 16 September 2008
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (6) , 705-710
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Congenital Glioblastoma: A Clinicopathologic and Genetic AnalysisBrain Pathology, 2007
- Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progressionPathology International, 2006
- Clinical Studies with Targeted Toxins in Malignant GliomaReviews on Recent Clinical Trials, 2006
- Emmprin Promotes Anchorage-Independent Growth in Human Mammary Carcinoma Cells by Stimulating Hyaluronan ProductionCancer Research, 2004
- Prognostic impact of matrix metalloproteinase‐9 in operable non‐small cell lung cancerInternational Journal of Cancer, 2002
- The Precrystalline Cytoplasmic Granules of Alveolar Soft Part Sarcoma Contain Monocarboxylate Transporter 1 and CD147The American Journal of Pathology, 2002
- Tumorigenic Potential of Extracellular Matrix Metalloproteinase InducerThe American Journal of Pathology, 2001
- Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions.2001
- Expression and Tissue Localization of Membrane-Type 1, 2, and 3 Matrix Metalloproteinases in Human Astrocytic TumorsThe American Journal of Pathology, 1999
- The New WHO Classification of Brain TumoursBrain Pathology, 1993